Q-omics provides the consensus-scored CDC73 profile across patient tissues and cancer cell-line models. CDC73 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CDC73 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, CDC73 protein abundance shows 30,652 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, HNSC, and GBM as cancer lineages where CDC73 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDC73 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDC73 survival associations across molecular data types. CDC73 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDC73 RNA expression–survival associations across cancer types. High CDC73 expression shows unfavorable associations in ACC, BLCA, KIRP, PAAD and UVM, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CDC73 RNA expression.
This table summarizes CDC73 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for CDC73. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDC73 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, LIHC, LUAD and BRCA. The HNSC box plot shows higher CDC73 RNA expression in tumor versus normal tissue (log2 FC = +0.875, t-test p < 0.001).
This table shows molecular features associated with CDC73 in patient tissues and cancer cell lines. In patient samples, CDC73 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CDC73 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
